KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Free Cash Flow (2016 - 2025)

Pacira BioSciences has reported Free Cash Flow over the past 16 years, most recently at $57.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $57.3 million for Q4 2025, up 104.9% from a year ago — trailing twelve months through Dec 2025 was $150.5 million (down 18.11% YoY), and the annual figure for FY2025 was $150.5 million, down 18.11%.
  • Free Cash Flow for Q4 2025 was $57.3 million at Pacira BioSciences, up from $57.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for PCRX hit a ceiling of $63.7 million in Q3 2021 and a floor of $5.0 million in Q1 2021.
  • Median Free Cash Flow over the past 5 years was $37.8 million (2022), compared with a mean of $36.6 million.
  • Biggest five-year swings in Free Cash Flow: soared 1078.29% in 2021 and later tumbled 83.21% in 2025.
  • Pacira BioSciences' Free Cash Flow stood at $21.1 million in 2021, then surged by 97.27% to $41.6 million in 2022, then fell by 18.59% to $33.9 million in 2023, then dropped by 17.44% to $28.0 million in 2024, then skyrocketed by 104.9% to $57.3 million in 2025.
  • The last three reported values for Free Cash Flow were $57.3 million (Q4 2025), $57.0 million (Q3 2025), and $9.3 million (Q2 2025) per Business Quant data.